ZeroHarm has acquired a manufacturing and R&D facility in the United States, and it also plans to launch in the UK, aside from the GCC markets
ZeroHarm Sciences, a clean-label Indian nutraceutical company, aims to accelerate its global footprint by focusing on expansion into the GCC markets, including the UAE and the broader Middle East. Following a 10× revenue growth over the past two years and operating at a ~20 per cent EBITDA margin, the company closed the last fiscal year with 71 crore in gross revenue with an exit ARR of 90 crores. In the current fiscal year, ZeroHarm is aiming for ₹150 crore in gross revenue, driven by domestic and global momentum and the United States contributing to nearly 30 per cent of its overall revenue.
ZeroHarm’s patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, enhancing their bioavailability by up to 5×, ensuring faster onset, precise dosing, and residue-free delivery. ZeroHarm’s US FDA, CE, and ISO-certified formulations are backed by government-led clinical trials, with documented claims for 15 products.
The company offers over 70 targeted, condition-specific products spanning diabetes, arthritis, PCOS, liver and kidney health, immunity, and oncology support. Backed by a fully owned, nanotech-enabled manufacturing facility, ZeroHarm can reportedly produce up to ₹250 crore worth of finished goods annually.
To support its international expansion, ZeroHarm has acquired a dedicated manufacturing and R&D facility in the United States to enhance local supply chain efficiency, fast-track formulation innovation, and enable closer clinical and regulatory collaborations.
With distribution agreements and regulatory filings already underway, the company also aims to launch in the UK, aside from the GCC markets, by Q3 2025, introducing its clinically tested product lines via pharmacies, e-commerce platforms, and integrative practitioner networks.
